166 related articles for article (PubMed ID: 20577872)
1. Osteoporosis quality indicators using healthcare utilization data.
Cadarette SM; Jaglal SB; Raman-Wilms L; Beaton DE; Paterson JM
Osteoporos Int; 2011 May; 22(5):1335-42. PubMed ID: 20577872
[TBL] [Abstract][Full Text] [Related]
2. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
3. Minimal error in self-report of having had DXA, but self-report of its results was poor.
Cadarette SM; Beaton DE; Gignac MA; Jaglal SB; Dickson L; Hawker GA
J Clin Epidemiol; 2007 Dec; 60(12):1306-11. PubMed ID: 17998086
[TBL] [Abstract][Full Text] [Related]
4. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
5. Rates of osteoporosis screening and treatment following vertebral fracture.
Barton DW; Behrend CJ; Carmouche JJ
Spine J; 2019 Mar; 19(3):411-417. PubMed ID: 30142455
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.
Ito K; Leslie WD
Osteoporos Int; 2015 Aug; 26(8):2111-9. PubMed ID: 25807913
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis.
Shetty S; John B; Mohan S; Paul TV
Arch Osteoporos; 2020 Feb; 15(1):25. PubMed ID: 32095943
[TBL] [Abstract][Full Text] [Related]
8. Cost and management of males with closed fractures.
Brenneman SK; Yurgin N; Fan Y
Osteoporos Int; 2013 Mar; 24(3):825-33. PubMed ID: 22776864
[TBL] [Abstract][Full Text] [Related]
9. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results.
Brask-Lindemann D; Cadarette SM; Eskildsen P; Abrahamsen B
Osteoporos Int; 2011 May; 22(5):1493-501. PubMed ID: 20683704
[TBL] [Abstract][Full Text] [Related]
11. Compliance with osteoporosis treatment guidelines in postmenopausal women.
Mountjoy CR; Shrader SP; Ragucci KR
Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838
[TBL] [Abstract][Full Text] [Related]
12. Targeted assessment of fracture risk in women at midlife.
Davis SR; Tan A; Bell RJ
Osteoporos Int; 2015 Jun; 26(6):1705-12. PubMed ID: 25630574
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU study.
Roux C; Cooper C; Díez-Pérez A; Martinez L; Ortolani S; Gitlin M; Möller G; Shepherd S; Freemantle N
Osteoporos Int; 2011 Apr; 22(4):1227-36. PubMed ID: 20628731
[TBL] [Abstract][Full Text] [Related]
14. Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice.
Lyu H; Yoshida K; Tedeschi SK; Zhao S; Xu C; Nigwekar SU; Leder BZ; Solomon DH
Osteoporos Int; 2019 Apr; 30(4):923-927. PubMed ID: 30680429
[TBL] [Abstract][Full Text] [Related]
15. US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50-64 years.
Bansal S; Pecina JL; Merry SP; Kennel KA; Maxson J; Quigg S; Thacher TD
Osteoporos Int; 2015 Apr; 26(4):1429-33. PubMed ID: 25614141
[TBL] [Abstract][Full Text] [Related]
16. Extensive undertreatment of osteoporosis in older Swedish women.
Lorentzon M; Nilsson AG; Johansson H; Kanis JA; Mellström D; Sundh D
Osteoporos Int; 2019 Jun; 30(6):1297-1305. PubMed ID: 30805678
[TBL] [Abstract][Full Text] [Related]
17. Use of antiosteoporotic medication in the Danish ROSE population-based screening study.
Høiberg MP; Rubin KH; Holmberg T; Rothmann MJ; Möller S; Gram J; Bech M; Brixen K; Hermann AP
Osteoporos Int; 2019 Jun; 30(6):1223-1233. PubMed ID: 30911782
[TBL] [Abstract][Full Text] [Related]
18. Pulse-echo ultrasound method for detection of post-menopausal women with osteoporotic BMD.
Karjalainen JP; Riekkinen O; Kröger H
Osteoporos Int; 2018 May; 29(5):1193-1199. PubMed ID: 29460101
[TBL] [Abstract][Full Text] [Related]
19. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
20. Identifying postmenopausal women with osteoporosis by calcaneal ultrasound, metacarpal digital X-ray radiogrammetry and phalangeal radiographic absorptiometry: a comparative study.
Boonen S; Nijs J; Borghs H; Peeters H; Vanderschueren D; Luyten FP
Osteoporos Int; 2005 Jan; 16(1):93-100. PubMed ID: 15197540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
